{
  "broker": {
    "id": 25203,
    "name": "Cantor Fitzgerald & Co., Research Division",
    "encrypt": "c47ccf5c-b413-4905-95b8-7eb1df8e81dc"
  },
  "type": {
    "id": 7334,
    "name": "Company Note"
  },
  "authors": [
    {
      "id": 38475,
      "firstName": "Li",
      "lastName": "Watsek",
      "email": "Li.Watsek@cantor.com"
    },
    {
      "id": 75248,
      "firstName": "Rosemary",
      "lastName": "Li",
      "email": "Rosemary.Li@cantor.com"
    }
  ],
  "issuers": [
    {
      "securities": [
        {
          "id": 518545,
          "name": "Oncternal Therapeutics, Inc.",
          "symbol": "ONCT",
          "bloomberg": "ONCT",
          "ratingAction": "Reiterate",
          "targetPriceAction": "Reiterate",
          "updated": 1697495400000
        }
      ]
    }
  ],
  "industries": [
    {
      "id": 57448,
      "gics": 352010,
      "name": "Biotechnology",
      "updated": 1717583736000
    }
  ],
  "brokerTags": [],
  "id": 12003785,
  "brokerDocId": 79910,
  "encrypt": "d7a43211-fd4f-406f-bbce-28e018884d3c",
  "title": "4Q Update: ROR1 CAR-T On-Track to Drive the Data Car This Year",
  "titleFormatted": "4Q Update: ROR1 CAR-T On-Track to Drive the Data Car This Year",
  "synopsis": "Investment Summary: We reiterate our Overweight rating and 12-month price target of $4. Today (3/9), Oncternal released 4Q22 financial results and held a company call. We view today's update as incremental, with key milestones remaining on-track. We see this year as an execution year for the Ph3 ZILO-301 in R/R MCL (relapsed/refractory mantle cell lymphoma). ONCT-808 (ROR1 CAR-T) will drive the data flow in aggressive B-cell lymphoma later this year, and the third program, ONCT-534, is guided to...",
  "publishTimestamp": 1678410221000,
  "updatedTimestamp": 1678410310000,
  "htmlLink": "https://research-exp.bluematrix.com/docs/html/c47ccf5c-b413-4905-95b8-7eb1df8e81dc/d7a43211-fd4f-406f-bbce-28e018884d3c",
  "rixmlLink": "https://research-exp.bluematrix.com/docs/rixml/c47ccf5c-b413-4905-95b8-7eb1df8e81dc/d7a43211-fd4f-406f-bbce-28e018884d3c",
  "pdfLink": "https://research-exp.bluematrix.com/docs/pdf/c47ccf5c-b413-4905-95b8-7eb1df8e81dc/d7a43211-fd4f-406f-bbce-28e018884d3c",
  "externalLink": false,
  "pdfLengthNumPages": 7,
  "assetClasses": [
    "Equity"
  ],
  "assetTypes": [
    "Stock"
  ],
  "countries": [
    "US"
  ],
  "productCategory": "Report",
  "focus": "Issuer"
}